Science & Enterprise subscription

Follow us on Twitter

  • A company developing graphene bio-computer chips is applying its technology to sensors that quickly detect SARS-CoV… https://t.co/Gl4q8GAZBg
    about 2 hours ago
  • New post on Science and Enterprise: Sensor in Works Detecting Covid-19 Airborne Virus https://t.co/gQ7LuZ5Qv1 #Science #Business
    about 2 hours ago
  • A company designing microscale robotic devices to deliver therapies to the central nervous system began work in pub… https://t.co/SUbHXwULXG
    about 4 hours ago
  • New post on Science and Enterprise: Micro Robotic Neuro Therapy Company Underway https://t.co/Lfm9Nysgd3 #Science #Business
    about 4 hours ago
  • National Science Foundation is funding a new system that uses artificial intelligence to find optimal combinations… https://t.co/jbZAJqQpmT
    about 1 day ago

Please share Science & Enterprise

Infographic – Late Charge Boosts Biotech Index

Nasdaq biotech index chart

Click on image for full-size view (Nasdaq)

26 Dec. 2020. The Nasdaq Biotechnology Index, an indicator of investor interest in the industry, rose in December to close up by 26 percent for the year. However, the Biotech Index underperformed the Nasdaq composite index, a financial indicator of the overall technology sector, since the start of 2020.

Changes in the Nasdaq Biotechnology Index, or NBI, largely mirrored share price movements overall throughout the year. In mid-March 2020, the NBI dropped by nearly a quarter (-24%) from its opening score of 3,878.91 on 2 January, a result the pandemic shock that drove down all share prices. The index then rebounded to 4,297.48 by the end of June, a gain of 45 percent from its mid-March trough.

We last visited the NBI in August, where we found the index maintaining its gains from spring. The Biotech Index continued on cruise control through summer and most of the fall, ranging from 4,000 to 4,500 points. Since the end of November, the NBI rose steadily to reach 4,901.92, its close on 24 December, a gain of 26 percent from the beginning of 2020.

While that increase is impressive, reflecting share prices of 282 biotech companies trading on the Nasdaq, the Nasdaq Composite Index, an indicator of the overall technology-heavy exchange, rose by 41 percent since the start of the year.

More from Science & Enterprise:

*     *     *

Comments are closed.